Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.
BullFrog AI Holdings, Inc. uses artificial intelligence and machine learning to turn complex biomedical data into actionable insights for drug discovery and development. Company news centers on the bfLEAP® platform, data harmonization through bfPREP™, and bfARENAS™, a scenario-based decision engine for pharmaceutical portfolio strategy, target selection, biomarker strategy and clinical trial design.
Recurring updates also cover commercial feasibility agreements with pharmaceutical customers, research-institution collaborations, white papers and conference participation in life sciences and oncology. Corporate news includes Nasdaq continued-listing compliance, at-the-market and equity-line financing activity, balance-sheet updates, and shareholder communications tied to the company’s common stock and tradable warrants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) announced the filing of its Form 10-K with the SEC for the year ending December 31, 2022. This filing, essential for compliance, was initially delayed due to the complexities surrounding its first-time submission, which led to a notice from Nasdaq regarding non-compliance with listing requirements. Following this completed filing, the company has restored its compliance. CEO Vin Singh expressed confidence in avoiding future delays. BullFrog AI focuses on precision medicine through machine learning, collaborating with institutions like Johns Hopkins University to enhance drug development using their proprietary bfLEAP™ platform.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announced a strategic partnership with the Sage Group to advance its Phase 2 ready oncology asset targeting glioblastoma, a deadly brain cancer, along with a preclinical prodrug asset. The partnership will leverage Sage Group's clinical and regulatory expertise to identify joint venture opportunities for global clinical development.
The glioblastoma treatment market is projected to exceed $10 billion by 2030, growing from $5.1 billion in 2020, highlighting significant market potential. BullFrog AI has exclusive licenses from Johns Hopkins University for innovative formulations of mebendazole, which have undergone clinical trials, aiming to provide new treatment options for patients.
BullFrog AI Holdings (Nasdaq: BFRG) announced an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole, signed on October 13, 2022. This world-wide, royalty-bearing license allows BullFrog to commercialize N-substituted prodrugs that improve solubility and bioavailability compared to the original compound. The prodrugs target oncology treatments, notably glioblastoma, leveraging BullFrog's AI technology to enhance drug development efficiency. Vin Singh, the CEO, emphasized the potential of this asset in their oncology pipeline. BullFrog AI is committed to advancing precision medicine through machine learning in drug development, aiming to reduce costs and improve patient outcomes.
RedChip Companies will feature interviews with BullFrog AI (NASDAQ:BFRG) and Alarum Technologies Ltd. (NASDAQ:ALAR) on The RedChip Money Report this Saturday, April 15, at 7 p.m. ET. The program will be broadcast on Bloomberg TV, which reaches approximately 73 million homes in the U.S.
View the interviews online at:
BullFrog AI is focused on precision medicine using its proprietary bfLEAP™ AI platform to enhance drug development and patient therapy matching. Alarum Technologies provides internet access solutions, including privacy and cybersecurity for enterprises and consumers.